EUVIMEDEUVIMED entdecken
Crossref

Relaxin‐2 Inhibits Cervical Cancer Growth by Downregulating Kruppel‐Like Factor 5 (KLF5) Through the Inhibition of Hippo‐YAP and JAK2/STAT3 Signaling Pathways

Hairong Li, Mudasir Ahmad, Dongmei Zhou iD

Journal of Biochemical and Molecular Toxicology · 2026

DOI: 10.1002/jbt.70687 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Hairong Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, XD Group Hospital, Xi'an, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Uterine Cervical Neoplasms, Kruppel-Like Transcription Factors, Signal Transduction. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Xi'an International Medical Center Hospital, Youth.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer continues to pose significant health problems globally, often fueled by the persistent activity of KLF5, a prototypical oncogenic transcription factor responsible for enhanced cell proliferation, survival, and extensive tumor growth. Relaxin‐2 (RLN2), which is part of the relaxin peptide hormone family, is known to exert a wide range of biological effects such as remodeling tissues and having anti‐fibrotic effects. There is growing concern that RLN2 has anti‐cancer activity; nevertheless, its function as well as the molecular mechanisms involved in cervical cancer is largely unknown. The goal of this research was to analyze the anti‐tumor effect of RLN2 on cervical cancer and to determine its molecular mechanism, with particular emphasis on KLF5 and the cross‐talks modulated by Hippo‐YAP and JAK2/STAT3 signaling pathways. SiHa and C33A human cervical cancer cell lines were treated with recombinant RLN2 at different concentrations and times. The expression level of KLF5 along with the expression of constituent components of the cell cycle (Cyclin D1, PCNA, CDK4), apoptotic indicators (Bax, Bcl‐2, cleaved caspase 3, PARP), and proteins of Hippo‐YAP (YAP, pYAP, TEAD1/2) and JAK2/STAT3 (phospho‐JAK2, phospho‐STAT3) were evaluated by Western blotting. To validate KLF5's mediating role, analysis of proliferation and apoptosis‐associated proteins was done after siRNA‐induced silencing of KLF5. In addition, cell proliferation was further confirmed using the Sulforhodamine B (SRB) assay. Likewise, the wound healing assay was performed to evaluate the migratory potential in RLN2‐treated SiHa cells compared to controls. The anti‐tumor effect of RLN2 was assessed in vivo using a SiHa xenograft model in nude mice. The mice received intraperitoneal injections of RLN2 (20 μg/kg/day) for 21 days. Throughout the duration, tumor growth parameters were monitored, and upon excision, the tumors were subjected to immunohistochemical staining for Ki‐67 (a proliferation marker). KLF5 protein expression was markedly reduced in both the cervical cancer cell lines following RLN2 treatment. This was coupled with a reduction of cell growth markers Cyclin D1, PCNA, and CDK4 which suggested G1 phase cell cycle arrest. There was a pronounced induction of apoptosis as indicated by increased Bax/Bcl‐2 ratios along with greater amounts of cleaved caspase‐3 and cleaved PARP 3. Consistent with these findings, the SRB assay confirmed a robust inhibition of cell proliferation, while the wound healing assay supported the strong anti‐migratory potential of RLN2. In terms of mechanism, RLN2 blocked the Hippo‐YAP pathway by promoting phosphorylation and sequestration of YAP into the cytoplasm, and downregulation of TEAD1/2 transcription factors. STAT3 and JAK2/2 signaling pathways were simultaneously inhibited as evidenced by decreased phosphorylation of JAK2 and STAT3, key oncogenic transcription drivers. KLF5 knockdown by siRNA showed effect opposite to RLN2 treatment which suggests KLF5 is indeed acting a mediator of these anti‐tumor effects. In vivo, the addition of RLN2 resulted in substantial suppression of tumor volume and weight while causing no body weight changes. Examination of tumor tissue showed decreased Ki67 staining. This study makes it very clear that RLN2 has strong anti‐cancer properties in cervical cancer by increasing the expression of the KLF5. The anti‐proliferative and pro‐apoptotic activities are achieved by the simultaneous inhibition of the Hippo‐YAP and JAK2/STAT3 signaling pathways. These results underline the potential of RLN2 as a therapeutic target for treatment of advanced cervical cancer and necessitate further applied research to investigate its clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorUterine Cervical NeoplasmsKruppel-Like Transcription FactorsSignal TransductionProtein Serine-Threonine KinasesJanus Kinase 2RelaxinAdaptor Proteins, Signal TransducingTranscription FactorsDown-RegulationNeoplasm ProteinsFemaleHumansAnimalsHippo Signaling PathwayCell Line, TumorMiceYAP-Signaling ProteinsCell ProliferationMice, Nude

Stichwörter der Autor:innen

JAK2KLF5STAT3cervical cancerrelaxin

Substanzen

STAT3 Transcription FactorKruppel-Like Transcription FactorsKLF5 protein, humanSTAT3 protein, humanProtein Serine-Threonine KinasesJanus Kinase 2RelaxinJAK2 protein, humanYAP-Signaling ProteinsRLN2 protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, XD Group Hospital, Xi'an, China.
  • Department of Clinical Biochemistry, University of Kashmir, Srinagar, India.
  • Department of Reproductive Endocrinology, Xi'an International Medical Center Hospital, XI'an, China.

ORCID-Profile: Dongmei Zhou

Förderung

  • Xi'an International Medical Center Hospital, Youth

Zitieren

APA

Li, H., Ahmad, M., & Zhou, D. (2026). Relaxin‐2 Inhibits Cervical Cancer Growth by Downregulating Kruppel‐Like Factor 5 (KLF5) Through the Inhibition of Hippo‐YAP and JAK2/STAT3 Signaling Pathways. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70687

Vancouver

Li H, Ahmad M, Zhou D. Relaxin‐2 Inhibits Cervical Cancer Growth by Downregulating Kruppel‐Like Factor 5 (KLF5) Through the Inhibition of Hippo‐YAP and JAK2/STAT3 Signaling Pathways. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.70687

BibTeX
@article{Li2026,
  author = {Li, Hairong and Ahmad, Mudasir and Zhou, Dongmei},
  title = {Relaxin‐2 Inhibits Cervical Cancer Growth by Downregulating Kruppel‐Like Factor 5 (KLF5) Through the Inhibition of Hippo‐YAP and JAK2/STAT3 Signaling Pathways},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2026},
  doi = {10.1002/jbt.70687}
}
Kostenlos starten →